Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787979 | 0.92 | CASP3 (0.51) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL3781996 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL3779399 | 0.87 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL3791023 | 0.85 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL3780392 | 0.84 | ALDH1A1 (0.74) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL5154376 | 0.82 | GRIK1 (0.61) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL8479003 | 0.81 | CASP3 (0.62) | ALDH1A1KDM4ECASP3L3MBTL1MEN1 | |
| SCHEMBL3786372 | 0.80 | TSHR (0.50) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL3779409 | 0.78 | CASP3 (0.49) | KDM4EHPGDCASP3L3MBTL1DHODH | |
| SCHEMBL3786368 | 0.77 | MEN1 (0.59) | ALDH1A1CASP3L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1142586-B1 | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-7169951-B2 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1192950-B1 | THERAPEUTIC DRUGS FOR DERMATITIS EXHIBITING A BIPHASIC SKIN REACTION CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1114035-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-05-17 | — | — | EP | disclosed |
| CN-1216872-C | Quinazoline derivative and pharmaceutical use thereof | SUNTORY LTD (JP) | 2005-08-31 | — | — | CN | disclosed |
| US-6921766-B1 | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| EP-1192949-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192950-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DERMATITISES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| CN-1335778-A | Blood vessel lipid deposition inhibitor containing chymotrypsin inhibitor | SUNTORY LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1174151-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR VARIOUS EOSINOPHILIA-RELATED DISEASES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| CN-1319096-A | Quinazoline derivative and pharmaceutical use thereof | SUNTORY LTD (JP) | 2001-10-24 | — | — | CN | disclosed |
| EP-1142586-A1 | INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES | SUNTORY LIMITED (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1114035-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNTORY LIMITED (JP) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000010982-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEROF | SUNTORY LIMITED (JP) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | CMA1, SERPINB1, TSLP | ALDH1A1 3114/4885KDM4E 1816/4885HPGD 1523/4885 |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | CMA1, ACE, ACE2 | ALDH1A1 1525/4885KDM4E 2745/4885HPGD 932/4885 |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | CMA1, MMP1, SERPINB1 | ALDH1A1 460/4885KDM4E 2639/4885HPGD 610/4885 |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | ALDH1A1 3296/4885KDM4E 1961/4885HPGD 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.